Friess Associates’s Edwards Lifesciences EW Stock Holding History

Friess Associates’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-116,550	Closed	-$5.42M	–	116
2018 Q1	$5.42M	Buy	+116,550	New	+$5.06M	0.44%	73

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Friess Associates's EW Position: Q2 2018 in Review

Friess Associates sold out of Edwards Lifesciences (EW) in Q2 2018, closing a stake of 116,550 shares — an estimated $5.42M sold.

Friess Associates first reported a position in EW in Q1 2018 and held it in 1 quarter. The position peaked at $5.42M in Q1 2018. 838 funds tracked by Wall St. Rank hold EW as of Q2 2018.

Friess Associates reported no remaining Edwards Lifesciences position as of Q2 2018 after selling out during the quarter.
Friess Associates sold 116,550 Edwards Lifesciences shares in Q2 2018, an estimated $5.42M.
Friess Associates first reported a position in Edwards Lifesciences in Q1 2018 and held it in 1 quarter.
Friess Associates's Edwards Lifesciences position peaked at $5.42M in Q1 2018.
838 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2018.

Based on Friess Associates's 13F filing for Q2 2018, filed 14 Aug 2018.